Skip to main content

Advertisement

SpringerLink
Log in

Phthalocyanine-BODIPY dye: synthesis, characterization, and utilization for pattern recognition of CYFRA 21-1 in whole blood samples

  • Research Paper
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

Phthalocyanine-BODIPY dye (BODIPY = boron dipyrromethene) was synthesized, fully characterized, and used for molecular recognition of CYFRA 21-1, a lung cancer biomarker, from whole blood samples. Thin films of three magnesium oxides ((MgO) n , where n = 8, 9, or 10)) were deposited on a paper substrate, and they were immersed in a solution of phthalocyanine-BODIPY dye (1.17 × 10−3 mol/L) for the design of stochastic sensors. Limits of determination of picograms per milliliter magnitude order were recorded for the proposed stochastic sensors. CYFRA 21-1 was reliably identified and determined with recoveries higher than 95% and RSD lower than 1% in whole blood samples.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993;53:61–6.

    CAS  Google Scholar 

  2. Takada M, Masuda N, Matsuura E, Kusunoki Y, Matui K, Nakagawa K, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer. 1995;71:160–5.

    Article  CAS  Google Scholar 

  3. Pujol JL, Molinier O, Ebert W, Daures JP, Barlesi F, Buccheri G, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of metaanalysis in 2063 patients. Br J Cancer. 2004;90:2097–105.

    Google Scholar 

  4. Park SY, Lee JG, Kim J, Park Y, Lee SK, Bae MK, et al. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer. 2013;79:156–60.

    Article  Google Scholar 

  5. Doweck I, Barak M, Uri N, Greenberg E. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer. 2000;83:1696–701.

    Article  CAS  Google Scholar 

  6. Wang YX, Hu D, Yan X. Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci. 2013;17:2383–9.

    Google Scholar 

  7. Yan HJ, Wang RB, Zhu KL, Jiang SM, Zhao W, Xu XQ, et al. Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma. Chin Med J. 2012;125:1410–5.

    CAS  Google Scholar 

  8. Jeong S, Park Y, Cho Y, Kim YR, Kim HS. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer. Clin Chim Acta. 2012;414:93–100.

    Article  CAS  Google Scholar 

  9. Aggarwal P, Kehoe S. Serum tumour markers in gynaecological cancers. Maturitas. 2010;67:46–53.

    Article  CAS  Google Scholar 

  10. Sheng X, Du X, Zhang X, Li D, Lu C, Li Q, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J. 2009;50:455–64.

    Article  CAS  Google Scholar 

  11. Kuessel L, Wild J, Haslacher H, Perkmann T, Ristl R, Zeisler H, et al. Urine and serum concentrations of cytokeratin 19 in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2014;181:311–5.

    Article  CAS  Google Scholar 

  12. Chapman MH, Sandanayake NS, Andreola F, Dhar DK, Webster GJ, Dooley JS, et al. Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. J Clin Exp Hepatol. 2011;1:6–12.

    Article  CAS  Google Scholar 

  13. Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers. 2013;34:219–28.

    Article  CAS  Google Scholar 

  14. Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, et al. Serum CYFRA 21-1 one of the most reliable tumor marker for breast carcinoma. Cancer. 2000;89:1285–90.

    Article  CAS  Google Scholar 

  15. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumor marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer. 2004;91:873–8.

    CAS  Google Scholar 

  16. Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, et al. Cytokeratin 19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer. 2003;88:1894–9.

    Article  CAS  Google Scholar 

  17. Giovanella L, Treglia G, Verburg FA, Salvatori M, Geriani L. Serum cytokeratin19 fragments: a dedifferentiation marker in advanced thyroid cancer. Eur J Endocrinol. 2012;167:793–7.

    Article  CAS  Google Scholar 

  18. Isic T, Savin S, Cvejic D, Marecko I, Tatic S, Havelka M, et al. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. J Cancer Res Clin Oncol. 2010;136:1805–12.

    Article  CAS  Google Scholar 

  19. Zhu WQ, Yu JM, Sun XD, Xie P, Kong L. Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma. Biomarkers. 2010;15:602–7.

    Article  CAS  Google Scholar 

  20. Hasholzner U, Baumgartner L, Stieber P, Meier W, Hofmann K, Faten-Mohadam A. Significance of the tumor markers CA125 II, CA 72.4, ASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Res. 1994;14:2743–6.

    CAS  Google Scholar 

  21. Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer. 2001;11:277–82.

    Article  CAS  Google Scholar 

  22. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010;28:2159–66.

    Article  Google Scholar 

  23. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalogue of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24.

    Article  CAS  Google Scholar 

  24. Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990;111:567–80.

    Article  CAS  Google Scholar 

  25. Zhong LP, Zhu HG, Zhang CP, Chen WT, Zhang ZY. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2007;36:230–4.

    Article  Google Scholar 

  26. Paraio JM, Jorcano JL. Beyond structure: do intermediate filaments modulate cell signaling? BioEssays. 2002;24:836–44.

    Article  Google Scholar 

  27. Wu HH, Wang PH, Yeh JY, Chen YJ, Yen MS, Huang RL, et al. Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer. Taiwan J Obstet Gynecol. 2014;53:30–4.

    Article  CAS  Google Scholar 

  28. Romero S, Fernández C, Arriero JM, Espasa A, Candela A, Martín C, et al. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J. 1996;9:17–23.

    Article  CAS  Google Scholar 

  29. Xu RH, Liao CZ, Luo Y, Xu WL, Li K, Chen JX, et al. Optimal cut-off values for CYFRA 21-1 expression in NSCLC patients depend on the presence of benign pulmonary diseases. Clin Chim Acta. 2015;440:188–92.

    Article  CAS  Google Scholar 

  30. Luo JP, Qu SX, Liu JT, Wang B, Cai XX. Rapid detection of Cyfra 21-1 by optical-biosensing based on chemiluminescence immunoassay using bio-functionlized magnetic nanocomposites. Chin Sci Bull. 2013;58:2567–8.

    Article  CAS  Google Scholar 

  31. Wang Q, Lu JB, Wu B, Hao LY. Expression and clinicopathologic significance of proteolysis-inducing factor in non-small-cell lung cancer: an immunohistochemical analysis. Clin Lung Cancer. 2010;11:346–51.

    Article  Google Scholar 

  32. Patel JL, Erickson JA, Roberts WL, Grenache DG. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum. Clin Biochem. 2010;43:1449–52.

    Article  CAS  Google Scholar 

  33. Hanagiri T, Sugaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer. 2011;74:112–7.

    Article  Google Scholar 

  34. Paone G, De Angelis G, Greco S, Portalone L, De Marchis L, Galluccio G, et al. Evaluation of response to chemotherapy in patients affected with non-small cell lung cancer by means of three tumour markers elaborated by discriminant analysis. Respir Med. 1997;91:361–7.

    Article  CAS  Google Scholar 

  35. Lan WJ, Lan W, Wang HY, Yan L, Wang ZL. An on-bacterium flow cytometric immunoassay for protein quantification. J Pharm Biomed Anal. 2013;83:129–34.

    Article  CAS  Google Scholar 

  36. Fujita J, Ohtsukib Y, Bandoha S, Takashimac H, Uedaa Y, Wua F, et al. Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage. Respir Med. 2004;98:294–300.

    Article  CAS  Google Scholar 

  37. Cheng S, Hideshima S, Kuroiwa S, Nakanishi T, Osaka T. Label-free detection of tumor markers using field effect transistor (FET)-based biosensors for lung cancer diagnosis. Sensors Actuators B Chem. 2015;212:329–34.

    Article  CAS  Google Scholar 

  38. Bayley H, Cremer PS. Stochastic sensors inspired by biology. Nature. 2001;413:226–30.

    Article  CAS  Google Scholar 

  39. Braha O, Walker B, Cheley S, Kasianowicz JJ, Song L, Gouaux JE, et al. Designed protein pores as components for biosensors. Cell Chem Biol. 1997;4:497–505.

    CAS  Google Scholar 

  40. Göksel M, Durmuş M, Atilla D. Synthesis asymmetrically peptide conjugated zinc(II) phthalocyanine and comparison photophsicochemical properties via different fluorophores effect. Inorg Chim Acta. 2017;456:95–104.

    Article  Google Scholar 

  41. Atilgan S, Ozdemir T, Akkaya EU. Selective Hg(II) sensing with improved Stokes shift by coupling the internal charge transfer process to excitation energy transfer. Org Lett. 2010;12:4792–5.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a project within the frame PNII, Ideas 123/2011. IR Comnea-Stancu is thankful for the funding from the Sectorial Operational Programme Human Resources Development 2007–2013 of the Ministry of European Funds through Financial Agreement POSDRU/159/1.5/S/132395.

Author information

Authors and Affiliations

  1. Laboratory of Electrochemistry and PATLAB Bucharest, National Institute of Research for Electrochemistry and Condensed Matter, 202 Splaiul Independentei St., 060021, Bucharest, Romania

    Raluca-Ioana Stefan-van Staden & Ionela Raluca Comnea-Stancu

  2. Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 1-7 Polizu St., 011061, Bucharest, Romania

    Raluca-Ioana Stefan-van Staden & Ionela Raluca Comnea-Stancu

  3. Department of Chemistry, Gebze Technical University, PO Box 141, 41400, Gebze, Kocaeli, Turkey

    Hülya Yanık & Meltem Göksel

  4. Kosekoy Vocational School, Kocaeli University, PO Box 141, 41135, Kartepe, Kocaeli, Turkey

    Meltem Göksel & Mahmut Durmuş

  5. Low Temperature Plasma Laboratory, National Institute for Lasers, Plasma and Radiation Physics (NILPRP), 409 Atomistilor St., 077125, Magurele, Romania

    Anghel Alexandru

Authors
  1. Raluca-Ioana Stefan-van Staden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ionela Raluca Comnea-Stancu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hülya Yanık
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meltem Göksel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anghel Alexandru
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mahmut Durmuş
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raluca-Ioana Stefan-van Staden.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Electronic supplementary material

ESM 1

(PDF 160 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stefan-van Staden, RI., Comnea-Stancu, I.R., Yanık, H. et al. Phthalocyanine-BODIPY dye: synthesis, characterization, and utilization for pattern recognition of CYFRA 21-1 in whole blood samples. Anal Bioanal Chem 409, 6195–6203 (2017). https://doi.org/10.1007/s00216-017-0560-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00216-017-0560-y

Keywords

Search

Navigation